Lilly Partners With Entos to Develop Drugs Targeting the Nervous System

Eli Lilly has gained the exclusive rights to Entos Pharmaceuticals’ Fusogenix nucleic acid delivery platform for therapies targeting the nervous system.

Under the deal, Entos will receive an upfront payment of $50 million and is eligible to receive a further $400 million from Lilly in milestones-based payments in addition to royalties on sales.

Nucleic acid-based therapies “hold great promise in addressing the biologic cause of many serious diseases that have significant unmet medical need,” said Andrew Adams, vice president of Lilly Genetic Medicine. The companies did not say which neurologic diseases the therapeutics will target.